|
|
100 Cyberonics Blvd. Houston, TX 77058 USA phone:281.228.7262 fax:800.218.9332
|
|
| Symbol |
CYBX |
| Exchange |
Nasdaq |
| Founded |
1987 |
| Employees |
|
|
|
| www.cyberonics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Implantable medical devices for neurological disorders including epilepsy |
 |
| Management |
| Daniel J. Moore, President and Chief Executive Officer; Gregory H. Browne, Vice President, Finance and Chief Financial Officer; Milton M. Morris, Ph.D., Vice President, Research and Development; George E. Parker III, Vice President, Human Resources; James A. Reinstein, Vice President, Sales and Marketing and International General Manager; Randal L. Simpson, vice President, Operations; David S. Wise, Vice President, General Counsel and Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| neurology, disorders, epilepsy, implantable, device, psychiatry |
|
|
|
| Description |
|
Cyberonics, Inc. designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders. |
 |
| Products / Services |
VNS (vagus nerve stimulation) Therapy is a treatment approach now available specifically for treatment-resistant depression.
|
 |
| Market / Customers |
VNS Therapy is indicated for use as an adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.
|
 |
| Strategy |
The Company is currently focused on epilepsy, the world's second most prevalent neurological disorder.
|
 |
| Status |
| In 1997, Cyberonics received approval from the Food and Drug Administration to market VNS Therapy for the treatment of epilepsy. Since that time, more than 32,000 patients worldwide have been implanted with the device.
In July 2005 VNS Therapy was approved by the FDA as a long-term adjunctive treatment for treatment-resistant depression. |
 |
|
|
|
|
|
|